HBM BioVentures acquires more than 98% of Biomedicine's shares

An exchange and cash offer that HBM BioVentures Ltd made for the shares of fellow Swiss life science investor International BM Biomedicine Holdings Inc. has been accepted. Founded in 1997, International BM Biomedicine Holdings is a Swiss investment company offering private and institutional investors the opportunity to invest tax-efficiently in a portfolio of life science companies focused on research and development. Having acquired over 98% of the company's shares, HBM BioVentures now plans to merge International BM Biomedicine Holdings Inc. with one of its own wholly-owned subsidiaries. With this business combination, HBM BioVentures both expands its existing investments to include an attractive, complementary portfolio in the life sciences segment, and broadens its shareholder base. HBM BioVentures is a leading global venture capitalist company with assets of over Sfr 900m in the areas of life sciences, biotech and medical technology and expertise in a range of attractive therapeutic areas. HBM BioVentures' advisory organisation remains unchanged.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH